English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Using the modified crossed immunoelectrophoresis technique (Heparin in agarose), different patterns were obtained characterizing the various types of antithrombin III (AT-III) deficiency. 125J labelled and purified commercial (KABI, Stockholm) AT-III preparates were administered to patients of different types in order to determine the biological half-life of AT-III. Various methods, including crossed immunoelectrophoresis and disc electrophoresis as well as heparin-Sepharose 4B chromatography were applied for the characterization of the AT-III administered.  These techniques revealed the molecular heterogeneity of AT-III preparates, especially those labelled by 125J. In the light of these observations it became obvious that among the AT-III determinations the most reliable and most specific method is the quantitative measurement of the fast migrating AT-III component (I-AT-III1) obtained by the modified method of crossed immunoelectrophoresis. This component corresponds to the “natural” AT-III of fresh normal plasma.  Applying this technique, one of our propositi (B.I.) displayed a significant shortening of the biological half-life of AT-III (26 hrs) while the two others (M.L. and B.J.) had approximately normal time courses (55 and 52 hrs, respectively). The different biological half-life times of AT-III in these patients also support the assumption of the heterogeneity of the congenital AT-III deficiency.

Isotopic And Immunological Half-Life Determination Of Antithrombin III In Various Types Of Antithrombin III Deficiency